Annual costs of rheumatoid arthritis in Turkey

Rheumatology International

Volumn 30, Issue 5, 2010, Pages 637-641

  Malhan, Simten ^a   Akbulut, Lale Aktekin ^b   Bodur, Hatice ^b   Tulunay, Cankat F ^c  

^a BASKENT UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Annual cost; Rheumatoid arthritis; Turkey

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHROPLASTY; ARTICLE; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL BILLING; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SOCIAL SECURITY; TURKEY (REPUBLIC);

AMBULATORY CARE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROPLASTY; DIAGNOSTIC TESTS, ROUTINE; DRUG COSTS; HEALTH CARE COSTS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LENGTH OF STAY; NATIONAL HEALTH PROGRAMS; SOCIAL SECURITY; TIME FACTORS; TURKEY;

EID: 77951024478     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1040-2     Document Type: Article

References (20)

1. Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3):S265-S272. doi: 10.1186/ar578
2. Kacar C, Gilgil E, Tuncer T, Bütün B, Urhan S, Arikan V et al (2005) Prevalence of rheumatoid arthritis in Antalya, Turkey. Clin Rheumatol 24(3):212-214. doi:10.1007/s10067-004-1006-4 (Pubitemid 40867940)
3. Turkish Republic Ministry of Health Refik Saydam Hygiene Center Presidency School of Public Health, ''National Burden of Disease and Cost Effectiveness Study'' 2005
4. Fautrel B, Guillemin F (2002) Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 14:121-126. doi:10.1097/0000 2281-200203000- 200300008
5. Kobelt G, Eberhardt K, Geborek P (2004) TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 63:4-10. doi:10.1136/ard.2003.010629 (Pubitemid 38064595)
6. Lambert CM (2001) Medical therapy for rheumatoid arthritisvalue for money. Rheumatology 40:961-964. doi:10.1093/ rheumatology/40.9.961
7. Cooper NC (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39:28-33. doi:10.1093/ rheumatology/39.1.28
8. Brennan A, Bansback N, Reynolds A, Conway P (2004) Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43:62-72. doi: 10.1093/rheumatology/keg451 (Pubitemid 38088370)
9. Péntek M, Kobelt G, Czirják L, Szekanecz Z, Poor G, Rojkovich B et al (2007) Costs of rheumatoid arthritis in Hungary. J Rheumatol 34:1437
10. Liang MH, Larson M, Thompson M, Eaton H, McNamara E, Katz R et al (1984) Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 27:522-529. doi:10.1002/ art.1780270507
11. American College of Rheumatology (2002) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46(2):328-346. doi:10.1002/art.10148 (Pubitemid 34136570)
12. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66(1):34-45. doi: 10.1136/ard.2005.044354 (Pubitemid 46044858)
13. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M et al (2003) Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 30:891-896 (Pubitemid 36402796)
14. Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V et al (2003) OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 30:886-890
15. Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T et al (2008) Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 27:1119-1125. doi:10.1007/s10067-008- 0877-1
16. T.C. Saǧlik BakanliǧİlaçEczacilik Genel Müdürlüǧü TemelİlaçFiyat listesi
17. T.C. Sosyal Güvenlik Kurumu Saǧlik Uygulama Tebliǧi
18. Cowley P, Bodabilla L, Musgrove P, Saxenian H (1994) Content and Financing of an essential national package of health services, global assessments in the health sector, World Health Organization, pp 171-181
19. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH (1986) Multicenter study of annual health service utilization and cost in rheumatoid arthritis. Arthritis Rheum 29:488-493. doi: 10.1002/art.1780290405
20. Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M et al (1997) Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 24:1051-1060